Four-Times Daily ASA More Effective in Post-CABG Patients

This article originally appeared here.
Share this content:
Four-Times Daily ASA More Effective in Post-CABG Patients
Four-Times Daily ASA More Effective in Post-CABG Patients

FRIDAY, Jan. 16, 2015 (HealthDay News) -- For patients undergoing coronary artery bypass graft (CABG) surgery, four-times daily acetyl-salicylic acid (ASA) seems more effective than once-daily 81 mg or 325 mg ASA, according to a study published online Dec. 27 in the Journal of Thrombosis and Haemostasis.

Jeremy S. Paikin, M.D., from McMaster University in Hamilton, Canada, and colleagues conducted a randomized study involving 100 patients undergoing CABG surgery to compare the effects of ASA 81 mg once-daily, ASA 325 mg once-daily, and ASA 81 mg four-times daily. The authors compared the effect on serum thromboxane B2 (TXB2) suppression and arachidonate-induced platelet aggregation.

The researchers found that platelet counts decreased after surgery, reached a nadir on day two, then increased gradually. On the second or third postoperative day there was near complete suppression of TXB2; levels increased on subsequent days. Patients receiving ASA 81 mg once-daily had the most marked increase, while the increase was less evident with four-times daily ASA 81 mg. Median TXB2 levels were lower on postoperative day four with four-times daily ASA 81 mg versus once-daily ASA 81 mg or 325 mg. Suppression of platelet aggregation was more effective with ASA given four-times daily versus ASA 81 mg or 325 mg once-daily.

"Four-times daily ASA is more effective than ASA 81 mg and 325 mg once-daily at suppressing serum TXB2 formation and platelet aggregation immediately following CABG surgery," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »